MetaCap

Iambic Therapeutics Inc. (IAM)

NASDAQ: IAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

13.11-1.15 (-8.06%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IAM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$621.42M
EPS (TTM)
-$2.69
52-week range
9.60 – 25.00
Day range
12.77 – 14.00
Volume / Avg
281.91K / 714.92K
Beta
—

52-week range

$9.60$25.00

IAM stock today

Iambic Therapeutics (IAM) closed at $13.11 on Nov 20, down 8.06% (-$1.15), versus the S&P 500's 3.70% decline. Trading was light, with 281.91K shares changing hands, about 39% of the average daily volume. Shares are 47.6% below their 52-week high of $25.00, set on Oct 16, 2026 and 36.6% above the 52-week low of $9.60, in the middle of the past year's range.

Iambic Therapeutics has posted a net loss over the last twelve months (EPS of -$2.69), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Iambic Therapeutics

Company profile

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Thomas Miller Ph.D.
Headquarters
San Diego, CA
Employees
171
IPO year
2026
Website
iambic.ai

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$27.25+107.86%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $22.00High $35.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-6.23 vs $-0.33
Surprise
-1787.88%

IAM news

All IAM news

Iambic Therapeutics peers

Health Care sector
IAM peer companies
CompanyPrice% ChgMarket capCompare
SRZNSurrozen Inc.28.46-7.21%$596.40Mvs IAM
CGEMCullinan Therapeutics Inc.8.89-1.98%$577.15Mvs IAM
FDMT4D Molecular Therapeutics Inc.10.23-4.57%$576.76Mvs IAM
ENTXEntera Bio Ltd.3.31+0.76%$575.53Mvs IAM
DBVTDBV Technologies S.A. ADR9.02-4.25%$566.82Mvs IAM
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs IAM
SLDBSolid Biosciences Inc.6.25-2.95%$697.57Mvs IAM
AURAAura Biosciences Inc.6.87-1.58%$714.99Mvs IAM

Indexes, lists and sector

Iambic Therapeutics stock FAQ

What is Iambic Therapeutics's stock price today?

IAM last traded at $13.11 as of Nov 20, 4:00 PM EST, down 8.06% on the day. Prices are delayed at least 15 minutes.

Who is Iambic Therapeutics's CEO?

Dr. Thomas Miller Ph.D. is the chief executive officer of Iambic Therapeutics Inc., which has about 171 employees.

What is the IAM 52-week high?

The 52-week high for IAM is $25.00 and the 52-week low is $9.60. The stock is currently 47.6% below its high.

Compare IAM